An experimental skin cancer vaccine developed by Merck and Moderna has shown significant efficacy in reducing the risk of melanoma recurrence and spread in a late-stage clinical trial. The Phase 3 trial, known as INTerpath-001, involved 1,137 patients worldwide who had undergone surgery for high-risk melanoma (Stage IIB to Stage IV). Participants were assigned to receive either Keytruda in combination with the personalized vaccine or Keytruda with a placebo.
The results indicated that patients who received the combination treatment experienced improved recurrence-free survival and distant metastasis-free survival compared to those who received Keytruda alone. Stéphane Bancel, CEO of Moderna, stated that these findings represent a significant advancement in cancer research, particularly in the development of mRNA treatments tailored to individual patients.
The personalized mRNA vaccine, known as intismeran autogene, is administered post-surgery to help the immune system target residual cancer cells. The vaccine is designed based on the genetic analysis of the patient's tumor, selecting specific neoantigens to enhance its effectiveness.
Dr. Murad Alam, chief of dermatology at Northwestern Medicine, emphasized the individualized nature of this approach, which aims to direct the immune response specifically toward cancer cells while minimizing impact on normal cells. The vaccine is intended for patients with advanced melanoma and is not designed for prevention in individuals without the disease.
Following the successful trial results, Merck and Moderna plan to engage with regulatory authorities, including the U.S. Food and Drug Administration, regarding potential regulatory filings. The companies also intend to explore the application of this vaccine technology for other challenging cancers such as lung, bladder, and kidney cancers.
While the trial results are promising, they are preliminary, and further research is needed to determine the long-term benefits and overall survival rates associated with the treatment. The side effects reported were consistent with previous studies, indicating a favorable safety profile.